BAKER BROS. ADVISORS LP
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$21.04B2026 Q3
Positions80
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.77.2%
What Changed This Quarter?
Top Holdings
INCY
Incyte
17.7%
ONC
BeOne Medicines
15.4%
RVMD
Revolution Medicines
10.4%
KOD
Kodiak Sciences
9.8%
MDGL
Madrigal Pharmaceuticals
5.1%
INSM
Insmed
4.8%
KYMR
Kymera Therapeutics
4.6%
ACAD
Acadia Pharmaceuticals
4.1%
New / Increased
5 new · 9 increased
TRAXNEW
First Tracks Biotherapeutics
0.1%
SCTXNEW
Scribe Therapeutics
0.1%
FRNMNEW
Freenome
0.1%
QTTBNEW
Q32 Bio
0.0%
Skye Bioscien…NEW
Skye Bioscience
0.0%
KOD
Kodiak Sciences
9.8%
+9.7%
CLDX
Celldex Therapeutics
0.4%
+116.9%
ONC
BeOne Medicines
15.4%
+0.3%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.